4.18 (-%)
As of Nov 21, 2024
Source:
Diamedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein to be studied in patients.
| Country | United States |
| Headquarters | minneapolis, minnesota |
| Phone Number | (763) 496-5454 |
| Industry | manufacturing |
| CEO | Rick Pauls |
| Website | www.diamedica.com |